Synthesis and antibacterial activity of C6-carbazate ketolides. 2006

Manomi A Tennakoon, and Todd C Henninger, and Darren Abbanat, and Barbara D Foleno, and Jamese J Hilliard, and Karen Bush, and Mark J Macielag
Johnson & Johnson Pharmaceutical Research & Development, L.L.C, 1000 Route 202, PO Box 300, Raritan, NJ 08869, USA. mtennako@prdus.jnj.com

A novel series of ketolides containing heteroaryl groups that are linked to the erythronolide ring via a C6-carbazate functionality has been successfully synthesized. Careful modulation of the heteroaryl groups, the length and degree of saturation of the C6-carbazate linker, and the substituents present on each of the carbazate nitrogens led to compounds with potent activity against key bacterial respiratory pathogens. The best analogs of this series had in vitro and in vivo (sc dosing) profiles that were comparable to telithromycin.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013210 Staphylococcus A genus of gram-positive, facultatively anaerobic, coccoid bacteria. Its organisms occur singly, in pairs, and in tetrads and characteristically divide in more than one plane to form irregular clusters. Natural populations of Staphylococcus are found on the skin and mucous membranes of warm-blooded animals. Some species are opportunistic pathogens of humans and animals.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D048628 Ketolides Compounds based on ERYTHROMYCIN with the 3-cladinose replaced by a ketone. They bind the 23S part of 70S bacterial RIBOSOMES. 3-Keto-Erythromycins,Erythromycins, 3-Keto,3 Keto Erythromycins,3-Keto Erythromycins,Erythromycins, 3 Keto

Related Publications

Manomi A Tennakoon, and Todd C Henninger, and Darren Abbanat, and Barbara D Foleno, and Jamese J Hilliard, and Karen Bush, and Mark J Macielag
February 2005, Bioorganic & medicinal chemistry letters,
Manomi A Tennakoon, and Todd C Henninger, and Darren Abbanat, and Barbara D Foleno, and Jamese J Hilliard, and Karen Bush, and Mark J Macielag
March 2006, Journal of medicinal chemistry,
Manomi A Tennakoon, and Todd C Henninger, and Darren Abbanat, and Barbara D Foleno, and Jamese J Hilliard, and Karen Bush, and Mark J Macielag
August 2006, Bioorganic & medicinal chemistry,
Manomi A Tennakoon, and Todd C Henninger, and Darren Abbanat, and Barbara D Foleno, and Jamese J Hilliard, and Karen Bush, and Mark J Macielag
September 2006, Bioorganic & medicinal chemistry letters,
Manomi A Tennakoon, and Todd C Henninger, and Darren Abbanat, and Barbara D Foleno, and Jamese J Hilliard, and Karen Bush, and Mark J Macielag
April 2010, Bioorganic & medicinal chemistry letters,
Manomi A Tennakoon, and Todd C Henninger, and Darren Abbanat, and Barbara D Foleno, and Jamese J Hilliard, and Karen Bush, and Mark J Macielag
December 2010, European journal of medicinal chemistry,
Manomi A Tennakoon, and Todd C Henninger, and Darren Abbanat, and Barbara D Foleno, and Jamese J Hilliard, and Karen Bush, and Mark J Macielag
December 2012, Bioorganic & medicinal chemistry letters,
Manomi A Tennakoon, and Todd C Henninger, and Darren Abbanat, and Barbara D Foleno, and Jamese J Hilliard, and Karen Bush, and Mark J Macielag
September 2007, Bioorganic & medicinal chemistry letters,
Manomi A Tennakoon, and Todd C Henninger, and Darren Abbanat, and Barbara D Foleno, and Jamese J Hilliard, and Karen Bush, and Mark J Macielag
August 2018, Bioorganic & medicinal chemistry letters,
Manomi A Tennakoon, and Todd C Henninger, and Darren Abbanat, and Barbara D Foleno, and Jamese J Hilliard, and Karen Bush, and Mark J Macielag
August 2001, The Journal of antibiotics,
Copied contents to your clipboard!